Type: Synthetic peptide Amino Acid Length: Modified sequence derived from GLP1, GIP, and glucagon analogs Molecular Weight: Approximately ~50006000 Da (varies slightly by formulation and modifications) Structure: Linear peptide with chemical modifications to enhance stability, receptor specificity, and half-life Receptor Targets: GLP1R, GIPR, and GCGR Multi-Receptor Activation: Engages three hormone receptors simultaneously for synergistic metabolic effects Appetite Regulation: Activates GLP1 and GIP pathways in the CNS and pancreas to reduce food intake Energy Metabolism: Stimulates GCGR-mediated energy expenditure and fat oxidation Insulin and Glucose Control: Enhances insulin secretion and glucose homeostasis through incretin pathways Stability: Chemically modified to resist enzymatic degradation and prolong in vivo activity Weight Management: Reduces body weight via appetite suppression and increased energy expenditure Glycemic Control: Improves fasting glucose, insulin sensitivity, and HbA1c levels Metabolic Health: Potentially improves lipid metabolism, cardiovascular markers, and overall metabolic profile Water-Soluble: Suitable for in vitro and preclinical research Modified Linear Peptide: Includes amino acid substitutions and chemical modifications for enhanced receptor affinity and pharmacokinetics Half-Life: Optimized for once-weekly dosing in clinical trials Retatrutide is a synthetic, multi-receptor peptide with biochemical properties tailored for simultaneous GLP1, GIP, and glucagon receptor activation
[DOI] [PMC free article] [PubMed] [Google Scholar] 32.Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ
Molecular Formula: CHNO
To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies
The GLP-1 patches, on the other hand, do not contain any GLP-1 drug
WeightWatchers centers on habit change, accountability, and community support while offering access to GLP-1s
